Clinic
ST Lukes Hospital-Anderson Campus
ST Lukes Hospital-Anderson Campus was paid $8.47M by Medicaid between Jan 2018 and Dec 2024, across 238 billing codes. Its largest line is 99283, emergency room visit (moderate) — 23% of everything it billed.
33Billing provider infoST LUKES HOSPITAL-ANDERSON CAMPUS
EASTON, PA 18045
EASTON, PA 18045
33aNPI1497050470assigned 01/21/2011
33bProvider typeInfusion Therapy Clinic/Center
28Total paid$8.47M
24GClaims203,524
24DCodes billed238
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WOLFE, SCOTT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 201 | $37K | |
| 2019 | 2,382 | $208K | |
| 2020 | 22,311 | $966K | |
| 2021 | 90,153 | $3.44M | |
| 2022 | 30,166 | $1.40M | |
| 2023 | 34,789 | $1.54M | |
| 2024incomplete | 23,522 | $878K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 23% | 14,920 | 14,421 | $1.93M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 11,495 | 10,973 | $1.71M |
| G0378 | Hospital observation service, per hour | 8.9% | 841 | 746 | $755K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6.9% | 7,296 | 6,935 | $588K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.4% | 3,315 | 3,124 | $544K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 2.8% | 2,272 | 2,240 | $237K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 1,206 | 1,167 | $204K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 1.9% | 4,400 | 1,558 | $164K |
| X0620 | 1.9% | 781 | 736 | $159K | |
| 80053 | Comprehensive metabolic panel | 1.7% | 15,214 | 14,077 | $147K |
| 99050 | 1.7% | 1,471 | 1,331 | $146K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 1,797 | 1,715 | $136K |
226 more codes
| 99203 | Doctor's office visit, new patient (routine) | 1.5% | 1,167 | $129K |
| 80050 | General health panel | 1.1% | 2,125 | $90K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 16,890 | $84K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,679 | $56K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,307 | $50K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 946 | $46K |
| 80061 | Lipid panel | <1% | 3,299 | $44K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 502 | $43K |
| X0616 | <1% | 231 | $42K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 678 | $39K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,107 | $37K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 475 | $36K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 471 | $34K |
| X0621 | <1% | 150 | $34K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 592 | $31K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,499 | $30K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 148 | $27K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 770 | $26K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 108 | $24K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 586 | $23K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 871 | $23K |
| 87631 | <1% | 164 | $22K | |
| 86003 | <1% | 152 | $22K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 383 | $22K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 434 | $21K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 278 | $21K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 475 | $20K |
| 86803 | <1% | 938 | $17K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,924 | $17K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 70 | $16K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 128 | $16K |
| 80081 | <1% | 190 | $15K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 93 | $15K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 410 | $14K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 649 | $14K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,787 | $14K |
| 93971 | <1% | 235 | $14K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 645 | $14K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 2,181 | $13K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 71 | $12K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,812 | $12K |
| 86480 | <1% | 167 | $11K | |
| 83690 | <1% | 2,676 | $11K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,632 | $11K |
| 74183 | <1% | 28 | $11K | |
| 97162 | <1% | 164 | $11K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 498 | $11K |
| 81001 | <1% | 3,913 | $10K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 768 | $10K |
| 97161 | <1% | 148 | $10K | |
| 76770 | <1% | 232 | $10K | |
| S9083 | Global fee urgent care centers | <1% | 88 | $9K |
| 71250 | <1% | 161 | $9K | |
| 82728 | <1% | 799 | $9K | |
| 84702 | <1% | 556 | $9K | |
| 83970 | <1% | 222 | $8K | |
| 73610 | <1% | 484 | $8K | |
| 83880 | <1% | 260 | $7K | |
| 76536 | <1% | 145 | $7K | |
| 85027 | <1% | 1,144 | $7K | |
| 86618 | <1% | 312 | $7K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,098 | $7K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 110 | $7K |
| 86235 | <1% | 169 | $6K | |
| 84153 | <1% | 292 | $6K | |
| 84484 | <1% | 940 | $6K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 25 | $6K |
| 84439 | <1% | 839 | $6K | |
| 82607 | <1% | 534 | $6K | |
| 73562 | <1% | 460 | $6K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 102 | $6K |
| 82784 | <1% | 323 | $6K | |
| 82570 | <1% | 857 | $6K | |
| 93017 | <1% | 166 | $5K | |
| 83540 | <1% | 684 | $5K | |
| 96367 | <1% | 235 | $5K | |
| 87070 | <1% | 721 | $5K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 394 | $5K |
| 83735 | <1% | 781 | $5K | |
| 87340 | <1% | 342 | $5K | |
| 85610 | <1% | 1,362 | $5K | |
| 85379 | <1% | 470 | $4K | |
| 86038 | <1% | 294 | $4K | |
| 87040 | <1% | 273 | $4K | |
| 86255 | <1% | 241 | $4K | |
| 73630 | <1% | 416 | $4K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 74 | $4K |
| 73030 | <1% | 311 | $4K | |
| 85730 | <1% | 722 | $4K | |
| 73130 | <1% | 367 | $4K | |
| 82043 | <1% | 475 | $3K | |
| 81003 | <1% | 1,255 | $3K | |
| 73502 | <1% | 190 | $3K | |
| 73564 | <1% | 191 | $3K | |
| 83550 | <1% | 639 | $3K | |
| 76801 | <1% | 84 | $3K | |
| 87536 | <1% | 24 | $3K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 73 | $3K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 27 | $3K |
| 96417 | <1% | 71 | $3K | |
| 82550 | <1% | 440 | $3K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 191 | $3K |
| 72100 | <1% | 151 | $3K | |
| 73221 | <1% | 12 | $3K | |
| J3490 | Unclassified drugs | <1% | 1,121 | $3K |
| 82785 | <1% | 149 | $3K | |
| 73110 | <1% | 260 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 46 | $2K |
| 83605 | <1% | 371 | $2K | |
| 82105 | <1% | 121 | $2K | |
| 72110 | <1% | 115 | $2K | |
| 86592 | <1% | 564 | $2K | |
| 87186 | <1% | 294 | $2K | |
| 86850 | <1% | 296 | $2K | |
| 86140 | <1% | 738 | $2K | |
| 84703 | <1% | 232 | $2K | |
| 84403 | <1% | 73 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 220 | $2K |
| 93970 | <1% | 26 | $2K | |
| 87077 | <1% | 292 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,148 | $2K |
| 86200 | <1% | 138 | $2K | |
| 82746 | <1% | 172 | $2K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 97 | $2K |
| 85652 | <1% | 617 | $2K | |
| 82950 | <1% | 250 | $2K | |
| 94729 | <1% | 61 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 197 | $2K |
| 86430 | <1% | 233 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,311 | $2K |
| 80076 | <1% | 178 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 923 | $1K |
| 76813 | <1% | 26 | $1K | |
| 84156 | <1% | 358 | $1K | |
| 85007 | <1% | 379 | $1K | |
| 83721 | <1% | 149 | $1K | |
| 86901 | <1% | 338 | $1K | |
| 84100 | <1% | 218 | $1K | |
| 86900 | <1% | 338 | $1K | |
| 74018 | <1% | 113 | $1K | |
| 86800 | <1% | 66 | $1K | |
| 86704 | <1% | 79 | $1K | |
| 84550 | <1% | 186 | $1K | |
| OP250 | <1% | 1,732 | $1K | |
| 82247 | <1% | 139 | $1K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 12 | $987.88 |
| 300 | Patient transfer system <300 | <1% | 64 | $924.36 |
| 94726 | <1% | 38 | $923.22 | |
| 86706 | <1% | 69 | $905.97 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 314 | $860.84 |
| 97165 | <1% | 12 | $806.88 | |
| J2704 | Injection, propofol, 10 mg | <1% | 4,114 | $797.34 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,196 | $747.24 |
| 82803 | <1% | 44 | $723.63 | |
| 86705 | <1% | 43 | $675.68 | |
| 84165 | <1% | 53 | $650.21 | |
| 84481 | <1% | 32 | $614.33 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,414 | $601.27 |
| 77334 | <1% | 14 | $594.00 | |
| 82948 | <1% | 406 | $574.33 | |
| 76870 | <1% | 14 | $570.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 281 | $555.71 |
| 93880 | <1% | 13 | $520.22 | |
| 73600 | <1% | 51 | $503.00 | |
| 83001 | <1% | 26 | $478.80 | |
| 90715 | <1% | 25 | $478.61 | |
| 86376 | <1% | 62 | $443.25 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 796 | $441.41 |
| 87522 | Neg quan hep c or qual rna | <1% | 16 | $417.92 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 805 | $416.24 |
| 93226 | <1% | 15 | $397.70 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,271 | $386.04 |
| 73140 | <1% | 39 | $374.93 | |
| 82805 | <1% | 12 | $373.05 | |
| 86160 | <1% | 14 | $371.62 | |
| 84146 | <1% | 14 | $345.60 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,660 | $327.65 |
| 73080 | <1% | 32 | $306.50 | |
| 84402 | <1% | 13 | $302.40 | |
| 93225 | <1% | 28 | $302.09 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 385 | $241.23 |
| 86762 | <1% | 13 | $231.76 | |
| 86787 | <1% | 12 | $224.04 | |
| 72050 | <1% | 13 | $219.68 | |
| 81025 | <1% | 196 | $218.76 | |
| 83002 | <1% | 12 | $216.92 | |
| 94060 | <1% | 24 | $207.31 | |
| 84145 | <1% | 13 | $204.33 | |
| 82553 | <1% | 26 | $202.41 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,738 | $202.33 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,103 | $195.43 |
| 73590 | <1% | 14 | $188.10 | |
| 81002 | <1% | 49 | $178.31 | |
| 86225 | <1% | 12 | $147.61 | |
| 83525 | <1% | 12 | $140.80 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,139 | $139.20 |
| 84132 | <1% | 34 | $135.54 | |
| 73560 | <1% | 14 | $133.98 | |
| 76830 | Ultrasound, transvaginal | <1% | 16 | $126.56 |
| 84295 | <1% | 32 | $125.94 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 17 | $95.18 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 75 | $91.00 |
| 85014 | <1% | 51 | $86.08 | |
| 82947 | <1% | 37 | $76.88 | |
| 87430 | <1% | 12 | $75.60 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,118 | $65.29 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 261 | $51.14 |
| 82077 | <1% | 48 | $42.12 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,169 | $39.72 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,365 | $4.60 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 144 | $0.05 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 97 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 237 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 73 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 15 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 31 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 13 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 17 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 780 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 101 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 39 | $0.00 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 33 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 61 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 18 | $0.00 |
| 80143 | 0% | 15 | $0.00 | |
| 80179 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWOLFE, SCOTT (SENIOR VP FINANCE/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.